Key regions: Australia, Japan, United States, Germany, Europe
Iran, a country known for its rich history and culture, is also experiencing a significant development in the Anti-Coagulants market.
Customer preferences: Iran's population is aging, and as a result, there is an increasing demand for Anti-Coagulants. The preference for oral anticoagulants is growing as they are more convenient and have a lower risk of bleeding compared to traditional anticoagulants like warfarin. Patients also prefer anticoagulants that require less frequent monitoring.
Trends in the market: Iran's Anti-Coagulants market is experiencing significant growth due to an increase in the prevalence of cardiovascular diseases, which is driving demand for anticoagulants. The market is also benefiting from the introduction of new oral anticoagulants that have a lower risk of bleeding and are more convenient to use. The market is expected to continue to grow as the population ages and the prevalence of cardiovascular diseases increases.
Local special circumstances: Iran's healthcare system is undergoing significant reforms, which include expanding health insurance coverage and improving access to healthcare services. These reforms are expected to increase the demand for Anti-Coagulants as more people will have access to healthcare services. Additionally, Iran's government is investing in medical research and development, which is expected to lead to the introduction of new anticoagulants in the market.
Underlying macroeconomic factors: Iran's economy is heavily dependent on oil exports, and as a result, the economy has been affected by fluctuations in oil prices. However, the government is implementing economic reforms to diversify the economy and reduce its reliance on oil. These reforms are expected to create new opportunities for businesses, including those in the Anti-Coagulants market. Additionally, Iran has a large and growing population, which presents a significant market opportunity for businesses operating in the country.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
